FDA Determines Regulatory Review Period for ANTISEDAN Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of ANTISEDAN, a veterinary drug product, as required by law. This decision was prompted by a submission to the U.S. Patent and Trademark Office, Department of Commerce, seeking to extend the patent term for this animal drug.